Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK233705 (Darotropium bromide) 是一种毒蕈碱受体拮抗剂,可用来与预防和治疗人类的慢性阻塞性肺病(COPD)和哮喘。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 910 | 现货 | ||
5 mg | ¥ 2,230 | 现货 | ||
10 mg | ¥ 3,360 | 现货 | ||
25 mg | ¥ 5,480 | 现货 | ||
50 mg | ¥ 7,680 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
500 mg | ¥ 19,800 | 现货 |
产品描述 | GSK233705 (Darotropium bromide) is a muscarinic receptor antagonist used in conjunction with the prevention and treatment of chronic obstructive pulmonary disease (COPD) and asthma in humans. |
体内活性 | Patients were randomized to receive 12.5 µg, 25 µg, 50 µg, 100 µg or 200 µg of GSK233705 or placebo once daily for 28 days. The primary endpoint was a change from baseline in trough forced expiratory volume in 1 s (FEV(1)) on day 29. RESULTS: The intent-to-treat population consisted of 576 patients (mean predicted FEV(1) 51%; mean age 62 years). Treatment with GSK233705 produced statistically significant improvements in pulmonary function compared with placebo. Only the 200 µg dose exceeded the predefined target threshold of 130-mL difference compared with placebo for the primary endpoint of change from baseline in trough FEV(1) on day 29. No clear pattern of dose-response was observed for the other doses. Serial FEV(1) (0-24 h) showed a peak effect around 2 h postdose and tended to decline to clinically insignificant levels compared with placebo at 23 and 24 h. Each dose of GSK233705 was well tolerated. The incidence of adverse events was low and similar across all treatment groups. There were no clinically significant effects on laboratory parameters, vital signs, or electrocardiograms. CONCLUSION: All doses of GSK233705 demonstrated bronchodilatory activity and were well tolerated. Although the onset of bronchodilation was rapid, it was not sustained over 24 h making it unsuitable for once-daily dosing.[2] |
别名 | Darotropium bromide, GSK 233705, GSK-233705B, GSK233705, GSK233705B, GSK-233705, GSK 233705B |
分子量 | 425.4 |
分子式 | C24H29BrN2 |
CAS No. | 850607-58-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK233705 850607-58-8 Neuroscience AChR Darotropium bromide GSK 233705 GSK-233705B GSK233705B GSK-233705 GSK 233705B Darotropium Bromide Inhibitor inhibitor inhibit